CSIMarket Company Name, Ticker, Suppliers, else..


Corcept Therapeutics Inc  (CORT)
Other Ticker:  
 

Corcept Therapeutics Inc

CORT's Fundamental analysis



Looking into Corcept Therapeutics Inc growth rates, revenue grew by 39.15 % in II. Quarter 2024 from the same quarter a year ago. Ranking at No. 767

Major Pharmaceutical Preparations industry recorded growth of revenues by 5.17 %

Corcept Therapeutics Inc's net income grew by 28.38 % in II. Quarter 2024 year on year, above company average,

• More on CORT's Growth


Corcept Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Corcept Therapeutics Inc PEG ratio is at 1.11 Corcept Therapeutics Inc realized cash reduction of $ -0.39 per share in trailing twelve-month period.
Company
40.09
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.97.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.75.


• More on CORT's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,618,210
 Net Income/Employee (TTM) $ 355,020
 Receivable Turnover (TTM) 11.92
 Tangible Book Value (Per Share $) 5.36

Corcept Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Corcept Therapeutics Inc PEG ratio is at 1.11 Corcept Therapeutics Inc realized cash outflow of $ -0.39per share in trailing twelve-month period.
Company
40.09
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.97.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.75.

Corcept Therapeutics Inc Price to Book Ratio is at 8.57 lower than Industry Avg. of 84.74. and higher than S&P 500 Avg. of 0

• More on CORT's Valuation

•  Market Capitalization (Millions $) 5,111
•  Shares Outstanding (Millions) 111
•  Employees 352
•  Revenues (TTM) (Millions $) 570
•  Net Income (TTM) (Millions $) 125
•  Cash Flow (TTM) (Millions $) -44
•  Capital Exp. (TTM) (Millions $) 0
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,618,210
•  Net Income/Employee(TTM) $ 355,020
•  Receivable Turnover Ratio (TTM) 11.92
•  Tangible Book Value (Per Share $) 5.36

•  Market Capitalization (Millions $) 5,111
•  Shares Outstanding (Millions) 111
•  Employees 352
•  Revenues (TTM) (Millions $) 570
•  Net Income (TTM) (Millions $) 125
•  Cash Flow (TTM) (Millions $) -44
•  Capital Exp. (TTM) (Millions $) 0


    CORT's Profitability Comparisons
Corcept Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 21.73 % from 20.09 % in I. Quarter.

Corcept Therapeutics Inc net profit margin of 21.44 % is currently ranking no. 22 in Major Pharmaceutical Preparations industry, ranking no. 47 in Healthcare sector and number 560 in S&P 500.


Profitability by Segment
Total 21.44 %



  Ratio
•   Capital Ratio (MRQ) 5.57
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.2
•  Asset Turnover Ratio (TTM) 1.04
•  Inventory Turnover Ratio (TTM) 1.11



Corcept Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 21.73 % from 20.09 % in I. Quarter.

Corcept Therapeutics Inc net profit margin of 21.44 % is currently ranking no. 22 in Major Pharmaceutical Preparations industry, ranking no. 47 in Healthcare sector and number 560 in S&P 500.

• More on CORT's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com